Program Description
Despite advances in therapies for patients with acute myeloid leukemia, the cure rate remains low, with just 5% to 15% of patients aged older than 60 years achieving cure. However, advancements in induction regimens as well as evolving maintenance therapy options have improved outcomes for this patient population. Despite the evolving landscape of AML therapy, older patients with AML undergoing treatment require additional considerations, and pharmacist-led efforts can assist in overcoming these challenges. This activity will examine clinical data for different combination therapies in the treatment landscape of AML, with analysis of cost-efficacy and medication access considerations. The role of managed care pharmacists in implementing clinical pathways and developing evidence-based treatment protocols for the management of older patients with AML to optimize utilization of resources for both patients and the healthcare system will also be examined.
Target audience: Managed care pharmacists, oncology pharmacists
Type of activity: Application
Release date: August 1, 2022
Expiration date: August 1, 2023
Time to complete activity: 2.0 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explore the clinical data for alternative induction regimens in older patients with acute myeloid leukemia (AML).
- Identify the challenges and recent advances in maintenance therapy for older patients with AML.
- Illustrate the managed care considerations in developing treatment pathways that address the unique needs of older patients with AML.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
